Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease

Bibliography

• National institute for health and clinical excellence. CG101 chronic obstructive pulmonary disease (update): full guideline 23 June 2010. Available from: http://www.nice.org [Last accessed 18 October 2014]
   Google Scholar
• Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011;155:179-91
   PubMed Web of Science ®Google Scholar
• Global initiative for chronic obstructive lung disease.global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Revised 2014. Available from: http://www.goldcopd.org/ [Last accessed 18 October 2014]
   Google Scholar
• Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Arch Bronconeumol 2012;48:247-57
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Novelli L, Matera MG. Inhaled corticosteroids for chronic obstructive pulmonary disease. Expert Opin Pharmacother 2013;14:2489-99
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Inhaled corticosteroids in COPD: a controversy. Respiration 2010;80:89-95
   PubMed Web of Science ®Google Scholar
• Price D, Yawn B, Brusselle G, Rossi A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J 2013;22:92-100
   PubMedGoogle Scholar
• Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest 2004;126:213-19
   PubMed Web of Science ®Google Scholar
• Irwin RS, Richardson ND. Side effects with inhaled corticosteroids: the physician’s perception. Chest 2006;130(1 Suppl):41S-53S
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Inhaled corticosteroids. Pharmaceuticals 2010;3:514-40
   Google Scholar
• Buhl R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma. Allergy 2006;61:518-26
   PubMed Web of Science ®Google Scholar
• Galván CA, Guarderas JC. Practical considerations for dysphonia caused by inhaled corticosteroids. Mayo Clin Proc 2012;87:901-4
   PubMed Web of Science ®Google Scholar
• Rachelefsky GS, Liao Y, Faruqi R. Impact of inhaled corticosteroid-induced oropharyngeal adverse events: results from a meta-analysis. Ann Allergy Asthma Immunol 2007;98:225-38
   PubMed Web of Science ®Google Scholar
• Gallivan GJ, Gallivan KH, Gallivan HK. Inhaled corticosteroids: hazardous effects on voice-an update. J Voice 2007;21:101-11
   PubMed Web of Science ®Google Scholar
• Hira D, Koshiyama S, Komase Y, et al. Dry mouth as a novel indicator of hoarseness caused by inhalation therapy. J Asthma 2014;10.3109/02770903.2014.971965
   PubMed Web of Science ®Google Scholar
• Yang IA, Fong KM, Sim EH, et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007;2:CD002991
   PubMed Web of Science ®Google Scholar
• Sobieraj DM, White CM, Coleman CI. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Clin Ther 2008;30:1416-25
   PubMed Web of Science ®Google Scholar
• Kurt E, Yildirim H, Kiraz N, et al. Oropharyngeal candidiasis with dry-powdered fluticasone propionate: 500/day versus 200 microg/day. Allergol Immunopathol (Madr) 2008;36:17-20
   PubMed Web of Science ®Google Scholar
• Ohbayashi H, Adachi M. Influence of dentures on residual inhaled corticosteroids in the mouths of elderly asthma patients. Respir Investig 2012;50:54-61
   Google Scholar
• Kennedy WA, Laurier C, Gautrin D, et al. Occurrence and risk factors of oral candidiasis treated with oral antifungals in seniors using inhaled steroids. J Clin Epidemiol 2000;53:696-701
   PubMed Web of Science ®Google Scholar
• Vestbo J, Hurd SS, Agusti AC, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-65
   PubMed Web of Science ®Google Scholar
• Shim C, Williams MH. Cough and wheezing from beclomethasone aerosol. Chest 1987;91:207-9
   PubMed Web of Science ®Google Scholar
• Bryant DH, Pepys J. Bronchial reactions to aerosol inhalant vehicle. BMJ 1976;1:1319-20
   PubMed Web of Science ®Google Scholar
• Barnes NC. The properties of inhaled corticosteroids: similarities and differences. Prim Care Respir J 2007;16:149-54
   PubMedGoogle Scholar
• Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:144-9
   PubMed Web of Science ®Google Scholar
• Calverley P, Anderson J, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89
   PubMed Web of Science ®Google Scholar
• Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009;34:641-7
   PubMed Web of Science ®Google Scholar
• Anzueto A, Ferguson GT, Feldman G, et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD 2009;6:320-9
   PubMedGoogle Scholar
• Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med 2008;102:1099-108
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013;1:210-23
   PubMed Web of Science ®Google Scholar
• Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013;68:1029-36
   PubMed Web of Science ®Google Scholar
• Janson C, Larsson K, Lisspers KH, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS). BMJ 2013;346:f3306
   PubMed Web of Science ®Google Scholar
• Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014;3:CD010115
   PubMed Web of Science ®Google Scholar
• DiSantostefano RL, Sampson T, Le HV, et al. Risk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: a new-user cohort study. PLoS One 2014;9:e97149
   PubMed Web of Science ®Google Scholar
• Sibila O, Laserna E, Mortensen EM, et al. Effects of inhaled corticosteroids on pneumonia severity and antimicrobial resistance. Respir Care 2013;58:1489-94
   PubMed Web of Science ®Google Scholar
• Finney L, Berry M, Singanayagam A, et al. Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease. Lancet Respir Med 2014;10.1016/S2213-2600(14)70169-9
   Google Scholar
• Calverley PMA. Inhaled corticosteroids as a cause of CAP. Eur Respir Mon 2014;63:234-42
   Google Scholar
• Singanayagam A, Chalmers JD. Budesonide and risk of pneumonia. Lancet 2009;374:2050
   PubMedGoogle Scholar
• Malo de Molina R, Mortensen EM, Restrepo MI, et al. Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalized with pneumonia. Eur Respir J 2010;36:751-7
   PubMed Web of Science ®Google Scholar
• Loke YK, Kwok CS, Wong JM, et al. Chronic obstructive pulmonary disease and mortality from pneumonia: meta-analysis. Int J Clin Pract 2013;67:477-87
   PubMed Web of Science ®Google Scholar
• Ni S, Fu Z, Zhao J, Liu H. Inhaled corticosteroids (ICS) and risk of mycobacterium in patients with chronic respiratory diseases: a meta-analysis. J Thorac Dis 2014;6:971-8
   PubMed Web of Science ®Google Scholar
• Chung WS, Chen YF, Hsu JC, et al. Inhaled corticosteroids and the increased risk of pulmonary tuberculosis: a population-based case-control study. Int J Clin Pract 2014;68:1193-9
   PubMed Web of Science ®Google Scholar
• Brassard P, Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases. Am J Respir Crit Care Med 2011;183:675-8
   PubMed Web of Science ®Google Scholar
• Kim JH, Park JS, Kim KH, et al. Inhaled corticosteroid is associated with an increased risk of TB in patients with COPD. Chest 2013;143:1018-24
   PubMed Web of Science ®Google Scholar
• Dong YH, Chang CH, Lin Wu FL, et al. Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: a systematic review and meta-analysis of randomized controlled trials. a systematic review and meta-analysis of randomized controlled trials. Chest 2014;145:1286-97
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Calverley PM, Anderson JA, et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest 2009;136:1456-65
   PubMed Web of Science ®Google Scholar
• Yang IA, Clarke MS, Sim EH, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;7:CD002991
   PubMed Web of Science ®Google Scholar
• Scanlon PD, Connett JE, Wise RA, et al. Loss of bone density with inhaled triamcinolone in Lung Health Study II. Am J Respir Crit Care Med 2004;170:1302-9
   PubMed Web of Science ®Google Scholar
• Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 2011;66:699-708
   PubMed Web of Science ®Google Scholar
• Kelly HW, Nelson HS. Potential adverse effects of inhaled corticosteroids. J Allergy Clin Immunol 2003;112:469-78
   PubMed Web of Science ®Google Scholar
• Lehouck A, Boonen S, Decramer M, Janssens W. COPD, bone metabolism, and osteoporosis. Chest 2011;139:648-57
   PubMed Web of Science ®Google Scholar
• Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010;123:1001-6
   PubMed Web of Science ®Google Scholar
• Rogliani P, Calzetta L, Segreti A, et al. Diabetes mellitus among outpatients with COPD attending a university hospital. Acta Diabetol 2014;10.1007/s00592-014-0584-0
   PubMed Web of Science ®Google Scholar
• Caughey GE, Preiss AK, Vitry AI, et al. Comorbid diabetes and COPD: impact of corticosteroid use on diabetes complications. Diabetes Care 2013;36:3009-14
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Chronic obstructive pulmonary disease: effects beyond the lungs. PLoS Med 2010;7:e1000220
   PubMed Web of Science ®Google Scholar
• Slatore CG, Bryson CL, Au DH. The association of inhaled corticosteroid use with serum glucose concentration in a large cohort. Am J Med 2009;122:472-8
   PubMed Web of Science ®Google Scholar
• Baker EH, Clark N, Brennan AL, et al. Hyperglycemia and cystic fibrosis alter respiratory fluid glucose concentrations estimated by breath condensate analysis. J Appl Physiol 2007;102:1969-75
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Rogliani P, et al. High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway. Am J Respir Cell Mol Biol 201247:509-16
   PubMed Web of Science ®Google Scholar
• Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-9
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Rennard S, Gerstein H, et al. Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids. Respir Med 2012;106:1487-93
   PubMed Web of Science ®Google Scholar
• Miller DP, Watkins SE, Sampson T, Davis KJ. Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of cataracts and glaucoma among chronic obstructive pulmonary disease patients in the UK General Practice Research Database. Int J Chron Obstruct Pulmon Dis 2011;6:467-76
   PubMed Web of Science ®Google Scholar
• Weatherall M, Clay J, James K, et al. Dose-response relationship of inhaled corticosteroids and cataracts: a systematic review and meta-analysis. Respirology 2009;14:983-90
   PubMed Web of Science ®Google Scholar
• Uboweja A, Malhotra S, Pandhi P. Effect of inhaled corticosteroids on risk of development of cataract: a meta-analysis development of cataract: a meta-analysis. Fundam Clin Pharmacol 2006;20:305-30
   PubMed Web of Science ®Google Scholar
• Wang JJ, Rochtchina E, Tan AG, et al. Use of inhaled and oral corticosteroids and the long-term risk of cataract. Ophthalmology 2009;116:652-7
   PubMed Web of Science ®Google Scholar
• Basoglu OK, Emre S, Bacakoglu F, Ates H. Glaucoma associated with metered-dose bronchodilator therapy. Respir Med 2001;95:844-5
   PubMed Web of Science ®Google Scholar
• Zervas E, Samitas K, Gaga M, et al. Inhaled corticosteroids in COPD: pros and cons. Curr Drug Targets 2013;14:192-224
   PubMed Web of Science ®Google Scholar
• Geller DE. Clinical side effects during aerosol therapy: cutaneous and ocular effects. J Aerosol Med 2007;20(Suppl 1):S100-8
   PubMedGoogle Scholar
• Tashkin DP, Murray HE, Skeans M, Murray RP. Skin manifestations of inhaled corticosteroids in COPD patients: results from Lung Health Study II. Chest 2004;126:1123-33
   PubMed Web of Science ®Google Scholar
• Capewell S, Reynolds S, Shuttleworth D, et al. Purpura and dermal thinning associated with high dose inhaled corticosteroids. BMJ 1990;300:1548-51
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999;340:1948-53
   PubMed Web of Science ®Google Scholar
• Cazzola M, Bettoncelli G, Sessa E, et al. Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration 2010;80:112-19
   PubMed Web of Science ®Google Scholar
• Ionescu AA, Schoon E. Osteoporosis in chronic obstructive pulmonary disease. Eur Respir J 2003;46(suppl):64s-75s
   Web of Science ®Google Scholar
• Dimai HP, Domej W, Leb G, Lau K. Bone loss in patients with untreated chronic obstructive pulmonary disease is mediated by an increase in bone resorption associated with hypercapnia. J Bone Miner Res 2001;16:2132-41
   PubMed Web of Science ®Google Scholar
• Mineo TC, Ambrogi V, Mineo D, et al. Bone mineral density improvement after lung volume reduction surgery for severe emphysema. Chest 2005;127:1960-6
   PubMed Web of Science ®Google Scholar
• Heianza Y, Arase Y, Tsuji H, et al. Low lung function and risk of type 2 diabetes in Japanese men: the Toranomon Hospital Health Management Center Study 9 (TOPICS 9). Mayo Clin Proc 2012;87:853-61
   PubMed Web of Science ®Google Scholar
• Wang X, Bao W, Liu J, et al. Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care 2013;36:166-75
   PubMed Web of Science ®Google Scholar
• Song Y, Klevak A, Manson JE, et al. Asthma, chronic obstructive pulmonary disease, and type 2 diabetes in the Women’s Health Study. Diabetes Res Clin Pract 2010;90:365-71
   PubMed Web of Science ®Google Scholar
• Müllerova H, Chigbo C, Hagan GW, et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med 2012;106:1124-33
   PubMed Web of Science ®Google Scholar
• Metlay JP, Kapoor WN, Fine MJ. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA 1997;278:1440-5
   PubMed Web of Science ®Google Scholar
• Festic E, Bansal V, Gajic O, Lee AS. Prehospital use of inhaled corticosteroids and point prevalence of pneumonia at the time of hospital admission: secondary analysis of a multicenter cohort study. Mayo Clin Proc 2014;89:154-62
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Stockley RA, Seemungal TAR, et al. Reported pneumonia in patients with COPD: findings from the INSPIRE studyChest 2011;139:505-12
   PubMed Web of Science ®Google Scholar